登革热疫苗Qdenga已在澳大利亚获准上市，面向特定旅行者群体接种1。该疫苗采用两剂注射方案，间隔三个月，全球已有数百万剂的使用记录1。在儿童和青少年中，该疫苗的预防效率约为80%，并能预防超过95%的住院病例1。
澳大利亚建议4岁及以上且曾感染过登革热的旅行者，以及计划长期或反复前往登革热高发地区的旅行者接种1。这一建议的出台与疾病风险状况密切相关——2025年澳大利亚已报告1900多例登革热确诊病例，主要为归国旅行者1。数据显示，在2012至2022年间，印度尼西亚、泰国和印度是澳大利亚旅行者感染登革热最多的地区1。
疫苗接种的成本约为两剂300澳元1。根据临床数据，约50%的接种者报告出现副作用，主要表现为注射部位疼痛或发红、头痛、疲劳或肌肉酸痛，大多数副作用持续1至3天1。
The dengue vaccine Qdenga has been approved for use among travellers in Australia. 1 The vaccine requires two doses administered three months apart, and has accumulated millions of doses in use globally. 1 Among children and adolescents, it prevents approximately 80% of dengue cases and over 95% of hospitalizations. 1
Australian health authorities recommend the vaccine for travellers aged four years and older who have previously had a dengue infection, as well as those planning extended or repeated visits to dengue-endemic regions. 1 Between 2012 and 2022, Indonesia, Thailand, and India were the destinations where Australian travellers most frequently contracted dengue. 1 In 2025, Australia has recorded over 1,900 confirmed dengue cases, primarily among returning travellers. 1 The vaccination course costs approximately 300 Australian dollars. 1
About half of vaccine recipients report side effects, predominantly injection site pain or redness, headache, fatigue, or muscle soreness, with most symptoms resolving within one to three days. 1
评论
还没有评论，欢迎留下第一条。